Bright Angel Therapeutics

Elion Therapeutics

This biotechnology company develops antifungal medicines to prevent and treat life-threatening infections in immunocompromised patients, such as organ transplant and oncology recipients.

F2G

This biopharmaceutical company develops novel antifungal therapies to treat patients with life-threatening rare and resistant fungal infections.

Viamet Pharmaceuticals

This company develops small molecule antifungal medicines for patients with chronic and life-threatening infections using a proprietary metalloenzyme inhibitor design platform.

Amplyx

This company develops antifungal and antiviral therapies for patients with compromised immune systems, such as cancer and transplant recipients.

Alevin Therapeutics

This biotechnology company develops small molecule integrin inhibitors to treat patients with life-threatening fibrotic diseases, including lung, liver and kidney conditions.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.

Augustine Therapeutics

This company develops small molecule inhibitors to treat patients with neuromuscular, neurodegenerative and cardio-metabolic diseases.

Radiant Biotherapeutics

This company develops multi-specific antibody therapies to treat patients with cancer and infectious diseases.